A 2-part, multi-center, open-label trial to study safety, tolerability and pharmacodynamic (PD) effects of siponimod in healthy cytochrome P450(CYP)2C9 poor metabolizers (PM) compared to extensive metabolizers (EM) at single and multiple doses

Next Previous
Trial Profile

A 2-part, multi-center, open-label trial to study safety, tolerability and pharmacodynamic (PD) effects of siponimod in healthy cytochrome P450(CYP)2C9 poor metabolizers (PM) compared to extensive metabolizers (EM) at single and multiple doses

Completed
Phase of Trial: Phase I

Latest Information Update: 06 May 2016

At a glance

  • Drugs Siponimod (Primary)
  • Indications Dermatomyositis
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 06 May 2016 New trial record
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top